Drug Trial Radar · NCT04565054
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
Last checked: Nov 20, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,260
Planned (sponsor's estimate)
Start
Sep 2, 2020
Primary completion
Jun 2028
Study completion Jul 2029
Sponsor
- Lead sponsor
- Women's Cancer Study Group GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eli Lilly and Company; Genomic Health®, Inc.
- First posted
- Sep 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with breast cancer, who have completed first line therapy (e.g., radiotherapy, chemotherapy, surgery), and who have to be identified with having a high risk of recurrence of cancer, will be eligible for the study. This patient group is currently offered a standard of care chemotherapy plus endocrine therapy (ET). The study investigates whether the patient group with high-risk early breast cancer benefits from treatment with the medication abemaciclib in combination with ET compared to ET alone.
Conditions
- Breast Cancer Female
Interventions
Abemaciclib 50 MG; 150mg 1-0-1 per osDrug
Experimental: Abemaciclib plus ET Abemaciclib 150 mg, 2 x daily, resulting in 300 mg/day, oral, 24 months plus endocrine treatment of physician´s choice
Primary outcomes
What the sponsor says the trial is designed to measure.
- invasive disease-free survival (iDFS)Time frame: at end of study, 3-6 years after start of study treatment
Locations
85 sites in 3 countries. Site status is shown where the registry gives one.
MediOnko-Institut GbR Praxiskliik Krebsheilkunde für Frauen/Brustzentrum
Berlin, Germany
Praxis für gynäkologische Onkologie im Brustzentrum City am Sankt Gertrauden KH
Berlin, Germany
HELIOS Klinikum Berlin-Buch GmbH
Berlin, Germany
Onkologisch-Hämatologische Schwerpunktpraxis
Bremen, Germany
AGAPLESION Diakonie-Klinikum Hamburg Gyn. Studienambulanz
Hamburg, Germany
Mammazentrum Hamburg MVZ GbR
Hamburg, Germany
Klinikum Mittelbaden Balg
Baden-Baden, Baden-Würtemberg, Germany
Praxis für interdisziplinäre Onkologie & Hämatologie
Freiburg im Breisgau, Baden-Wurttemberg, Germany
SLK Kliniken Heilbronn Klinik für Gynäkologie und Geburtshilfe
Heilbronn, Baden-Wurttemberg, Germany
MVZ für Hämatologie und Onkologie
Ravensburg, Baden-Wurttemberg, Germany
Universitätsklinikum Ulm Frauenheilkunde, Geburtshilfe
Ulm, Baden-Wurttemberg, Germany
GRN-Klinik Weinheim Gynäkologie und Geburtshilfe
Weinheim, Baden-Wurttemberg, Germany
Universitätsklinikum Tübingen Department für Frauengesundheit, Brustzentrum
Tübingen, Baden-Wüttenburg, Germany
Haematologie-Onkologie im Zentrum MVZ GmbH
Augsburg, Bavaria, Germany
Rotkreuzkliniken München, Interdisziplinbäres Brustzentrum
München, Bavaria, Germany
Klinikum der Universität München Campus Großhadern Frauenheilunde und Geburtsklinik
Munich, Bavaria, Germany
Medizinisches Zentrum für Hämatologie und Onkologie München MVZ GmbH
Munich, Bavaria, Germany
Hämatologisch-Onkologische Schwerpunktpraxis Würzburg & Kitzingen
Würzburg, Bavaria, Germany
Medizinische Universität Lausitz - Carl-Thiem Frauenklinik
Cottbus, Brandenburg, Germany
Klinikum Ernst von Bergmann gGmbH Brustzentrum
Potsdam, Brandenburg, Germany
Centrum für Hämatologie und Onkologie
Frankfurt a.M., Hesse, Germany
Brustzentrum, Elisabeth-Krankenhaus gGmbH
Kassel, Hesse, Germany
Gemeinschaftspraxis für Hämatologie und Onkologie
Langen, Hesse, Germany
St. Josefs-Hospital Wiesbaden GmbH Ambulanz der Frauenklinik, Brustzentrum
Wiesbaden, Hesse, Germany
Studien GbR Braunschweig Dr. Lorenz/Dr. Kreiss-Sender
Braunschweig, Lower Saxony, Germany
MVZ II der Niels Stensen Kliniken Onkologie u. Hämatologie
Georgsmarienhütte, Lower Saxony, Germany
MVZ Onkologische Kooperation Harz (GbR)
Goslar, Lower Saxony, Germany
Diakovere Krankenhaus gGmbH Henriettenstift Frauenklinik
Hanover, Lower Saxony, Germany
Medizinische Hochschule Hannover Frauenheilkunde
Hanover, Lower Saxony, Germany
MVM Medizinische Verwaltungs und Managementgesellschaft mbH
Leer, Lower Saxony, Germany
Pius-Hospital Oldenburg Hämatologie, Onkologie
Oldenburg, Lower Saxony, Germany
Klinikum Südstadt Rostock Frauenklinik
Rostock, Mecklenburg-Vorpommern, Germany
Stiftung Katholisches BrustCentrum Marienhospital
Aachen, North Rhine-Westphalia, Germany
Uniklinik RWTH Aachen Gynäkologie und Geburtsmedizin
Aachen, North Rhine-Westphalia, Germany
Evangelisches Krankenhaus Bergisch Gladbach gGmbH Brustzentrum,
Bergisch Gladbach, North Rhine-Westphalia, Germany
Onkologische Schwerpunktpraxis Bielefeld
Bielefeld, North Rhine-Westphalia, Germany
Gynäkologisches Zentrum Bonn PD Dr. med. Christian Kurbacher
Bonn, North Rhine-Westphalia, Germany
GYNONOVA GbR Schwerpunktpraxis für gynäkologische Onkologie
Cologne, North Rhine-Westphalia, Germany
St. Elisabeth-Krankenhaus GmbH, Brustzentrum - Senologie
Cologne, North Rhine-Westphalia, Germany
Kliniken der Stadt Köln Krankenhaus Köln-Holweide Medizinische Klinik Brustzentrum
Cologne, North Rhine-Westphalia, Germany
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.